Symbols / MSLE Stock $6.38 +4.93% Satellos Bioscience Inc.
MSLE (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteSatellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Ratings
Current target
$6.38
Low
$20.00
High
$40.00
Mean
$27.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-18 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2026-04-28 | init | Guggenheim | — → Buy | $23 |
| 2026-04-06 | init | Leerink Partners | — → Outperform | $20 |
| 2026-03-30 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2026-03-11 | init | Cantor Fitzgerald | — → Overweight | — |
- MSLE SEC Filings - Satellos Bioscience Inc 10-K, 10-Q, 8-K Forms - Stock Titan Sat, 06 Jun 2026 20
- symbol__ Stock Quote Price and Forecast - CNN Sat, 07 Feb 2026 19
- Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours - Stocktwits Mon, 09 Feb 2026 08
- Satellos Bioscience: Q1 Earnings Snapshot - KTVB Fri, 15 May 2026 11
- Biotech Satellos to discuss muscle disease therapies at June investor events - Stock Titan Wed, 27 May 2026 07
- This ‘Alpha Male’ Stock Is Profiting as the Strait of Hormuz Remains Closed. Should You Buy It Now? - Barchart Sun, 22 Mar 2026 07
- Satellos price target raised to $40 from $5 at Oppenheimer - Yahoo Finance Wed, 11 Feb 2026 08
- What date does Satellos Bioscience Inc.'s (MSLE) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research hu, 02 Apr 2026 22
- Satellos Bioscience Priced A $50 Million Stock Sale As It Lists On Nasdaq - Finimize Fri, 06 Feb 2026 08
- Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy (TSX:MSCL:CA) - Seeking Alpha ue, 02 Sep 2025 07
- Satellos Bioscience (NASDAQ: MSLE) to present SAT-3247 program at June investor conferences - Stock Titan Wed, 27 May 2026 07
- Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq - Business Wire hu, 05 Feb 2026 08
- Fresh $57.2M gives Satellos runway through 2027 as Duchenne trial starts - Stock Titan Fri, 27 Mar 2026 07
- Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States - Business Wire Fri, 06 Feb 2026 08
- Satellos Bioscience (MSLE) insiders report 1.14M shares, 7.35% stake - Stock Titan Fri, 15 May 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Gross Profit |
|
—
|
—
|
—
|
—
|
| Operating Expense |
|
26.46
+29.71%
|
20.40
+75.00%
|
11.66
+87.70%
|
6.21
|
| Research And Development |
|
18.43
+28.32%
|
14.36
+116.04%
|
6.65
+141.57%
|
2.75
|
| Selling General And Administration |
|
7.44
+36.43%
|
5.45
+19.37%
|
4.57
+56.53%
|
2.92
|
| General And Administrative Expense |
|
7.44
+36.43%
|
5.45
+19.37%
|
4.57
+56.53%
|
2.92
|
| Salaries And Wages |
|
5.06
+34.54%
|
3.76
+37.90%
|
2.73
+56.44%
|
1.74
|
| Other Gand A |
|
2.37
+40.64%
|
1.69
-8.15%
|
1.84
+56.67%
|
1.17
|
| Other Operating Expenses |
|
0.59
+3.15%
|
0.57
+30.83%
|
0.44
+49.47%
|
0.29
|
| Total Expenses |
|
26.46
+29.71%
|
20.40
+75.00%
|
11.66
+87.70%
|
6.21
|
| Operating Income |
|
-26.46
-29.71%
|
-20.40
-75.00%
|
-11.66
-87.70%
|
-6.21
|
| Total Operating Income As Reported |
|
—
|
-19.38
-66.23%
|
-11.66
-87.70%
|
-6.21
|
| EBITDA |
|
-26.45
-29.78%
|
-20.38
-72.18%
|
-11.84
-46.33%
|
-8.09
|
| Normalized EBITDA |
|
-26.85
-40.26%
|
-19.14
-79.82%
|
-10.65
-79.98%
|
-5.92
|
| Reconciled Depreciation |
|
0.00
-73.33%
|
0.01
+184.27%
|
0.01
-97.87%
|
0.25
|
| EBIT |
|
-26.46
-29.71%
|
-20.40
-72.22%
|
-11.84
-42.04%
|
-8.34
|
| Total Unusual Items |
|
0.40
+132.12%
|
-1.24
-3.90%
|
-1.19
+45.17%
|
-2.18
|
| Total Unusual Items Excluding Goodwill |
|
0.40
+132.12%
|
-1.24
-3.90%
|
-1.19
+45.17%
|
-2.18
|
| Special Income Charges |
|
0.00
+100.00%
|
-2.90
-804.64%
|
-0.32
+84.89%
|
-2.13
|
| Other Special Charges |
|
—
|
—
|
0.32
|
—
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
2.90
|
0.00
-100.00%
|
2.13
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-24.87
-20.54%
|
-20.63
-72.28%
|
-11.98
-43.57%
|
-8.34
|
| Pretax Income |
|
-24.70
-19.71%
|
-20.63
-72.28%
|
-11.98
-43.64%
|
-8.34
|
| Net Non Operating Interest Income Expense |
|
1.36
+35.59%
|
1.00
+15.10%
|
0.87
+1777.25%
|
0.05
|
| Interest Expense Non Operating |
|
—
|
0.00
-100.00%
|
0.13
|
0.00
|
| Net Interest Income |
|
1.36
+35.59%
|
1.00
+15.10%
|
0.87
+1777.25%
|
0.05
|
| Interest Expense |
|
—
|
0.00
-100.00%
|
0.13
|
0.00
|
| Interest Income Non Operating |
|
1.36
+35.59%
|
1.00
-0.18%
|
1.00
+2064.68%
|
0.05
|
| Interest Income |
|
1.36
+35.59%
|
1.00
-0.18%
|
1.00
+2064.68%
|
0.05
|
| Other Income Expense |
|
0.40
+132.12%
|
-1.24
-3.90%
|
-1.19
+45.17%
|
-2.18
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
-0.04
|
| Gain On Sale Of Security |
|
0.40
-76.11%
|
1.67
+291.19%
|
-0.87
-1665.17%
|
-0.05
|
| Tax Provision |
|
0.17
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.06
|
0.00
|
0.00
+100.00%
|
-0.57
|
| Net Income Including Noncontrolling Interests |
|
-24.87
-20.54%
|
-20.63
-72.28%
|
-11.98
-43.57%
|
-8.34
|
| Net Income From Continuing Operation Net Minority Interest |
|
-24.87
-20.54%
|
-20.63
-72.28%
|
-11.98
-43.57%
|
-8.34
|
| Net Income From Continuing And Discontinued Operation |
|
-24.87
-20.54%
|
-20.63
-72.28%
|
-11.98
-43.57%
|
-8.34
|
| Net Income Continuous Operations |
|
-24.87
-20.54%
|
-20.63
-72.28%
|
-11.98
-43.57%
|
-8.34
|
| Normalized Income |
|
-25.21
-29.99%
|
-19.39
-79.84%
|
-10.78
-60.08%
|
-6.74
|
| Net Income Common Stockholders |
|
-24.87
-20.54%
|
-20.63
-72.28%
|
-11.98
-43.57%
|
-8.34
|
| Diluted EPS |
|
-1.70
+21.30%
|
-2.16
-32.66%
|
-1.63
+42.45%
|
-2.83
|
| Basic EPS |
|
-1.70
+21.30%
|
-2.16
-32.66%
|
-1.63
+42.45%
|
-2.83
|
| Basic Average Shares |
|
14.60
+52.60%
|
9.56
+32.84%
|
7.20
+142.17%
|
2.97
|
| Diluted Average Shares |
|
14.60
+52.60%
|
9.56
+32.84%
|
7.20
+142.17%
|
2.97
|
| Diluted NI Availto Com Stockholders |
|
-24.87
-20.54%
|
-20.63
-72.28%
|
-11.98
-43.57%
|
-8.34
|
| Amortization |
|
—
|
—
|
0.00
-100.00%
|
0.25
|
| Amortization Of Intangibles Income Statement |
|
—
|
—
|
0.00
-100.00%
|
0.25
|
| Depreciation Amortization Depletion Income Statement |
|
0.01
-66.67%
|
0.01
+184.27%
|
0.01
-97.87%
|
0.25
|
| Depreciation And Amortization In Income Statement |
|
0.01
-66.67%
|
0.01
+184.27%
|
0.01
-97.87%
|
0.25
|
| Depreciation Income Statement |
|
0.01
-66.67%
|
0.01
+184.27%
|
0.01
+79.04%
|
0.00
|
| Insurance And Claims |
|
—
|
—
|
—
|
0.03
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
31.89
-37.16%
|
50.75
+51.53%
|
33.49
+633.23%
|
4.57
|
| Current Assets |
|
31.88
-37.17%
|
50.74
+66.46%
|
30.48
+1752.73%
|
1.65
|
| Cash Cash Equivalents And Short Term Investments |
|
27.71
-42.92%
|
48.55
+62.22%
|
29.93
+2011.07%
|
1.42
|
| Cash And Cash Equivalents |
|
9.80
-75.53%
|
40.07
+140.23%
|
16.68
+1076.69%
|
1.42
|
| Cash Equivalents |
|
5.42
-65.45%
|
15.69
-3.01%
|
16.18
+1875.96%
|
0.82
|
| Cash Financial |
|
4.38
-82.02%
|
24.39
+5211.85%
|
0.46
-23.36%
|
0.60
|
| Other Short Term Investments |
|
17.91
+111.28%
|
8.47
-36.02%
|
13.25
|
—
|
| Receivables |
|
0.37
-14.94%
|
0.43
-1.36%
|
0.44
+130.20%
|
0.19
|
| Accounts Receivable |
|
—
|
—
|
—
|
0.00
|
| Taxes Receivable |
|
0.37
-14.94%
|
0.43
-1.36%
|
0.44
+130.20%
|
0.19
|
| Prepaid Assets |
|
3.80
+116.14%
|
1.76
+1471.43%
|
0.11
+230.45%
|
0.03
|
| Hedging Assets Current |
|
0.00
|
0.00
-100.00%
|
0.00
+35.72%
|
0.00
|
| Total Non Current Assets |
|
0.01
+25.00%
|
0.00
-99.87%
|
3.01
+2.88%
|
2.92
|
| Net PPE |
|
0.01
+25.00%
|
0.00
-73.33%
|
0.01
+126.20%
|
0.01
|
| Gross PPE |
|
—
|
0.00
-75.68%
|
0.01
+38.84%
|
0.01
|
| Accumulated Depreciation |
|
—
|
—
|
-0.01
-252.87%
|
-0.00
|
| Machinery Furniture Equipment |
|
—
|
—
|
0.03
+210.22%
|
0.01
|
| Other Properties |
|
—
|
0.00
-75.68%
|
0.01
|
—
|
| Goodwill And Other Intangible Assets |
|
0.00
|
0.00
-100.00%
|
2.96
+2.62%
|
2.89
|
| Other Intangible Assets |
|
—
|
—
|
—
|
3.92
|
| Investments And Advances |
|
0.00
|
0.00
-100.00%
|
0.03
+0.17%
|
0.03
|
| Other Non Current Assets |
|
—
|
—
|
2.99
|
—
|
| Total Liabilities Net Minority Interest |
|
4.11
+14.57%
|
3.58
+31.05%
|
2.73
+31.12%
|
2.09
|
| Current Liabilities |
|
4.11
+14.57%
|
3.58
+31.05%
|
2.73
+31.12%
|
2.09
|
| Payables And Accrued Expenses |
|
4.11
+14.57%
|
3.58
+31.05%
|
2.73
+31.12%
|
2.09
|
| Payables |
|
1.84
-10.62%
|
2.06
+163.15%
|
0.78
-27.42%
|
1.08
|
| Accounts Payable |
|
1.77
-14.11%
|
2.06
+163.15%
|
0.78
-27.42%
|
1.08
|
| Current Accrued Expenses |
|
2.26
+48.75%
|
1.52
-21.96%
|
1.95
+93.81%
|
1.01
|
| Total Tax Payable |
|
0.07
|
0.00
|
—
|
—
|
| Income Tax Payable |
|
0.07
|
0.00
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
27.78
-41.09%
|
47.16
+53.35%
|
30.76
+1139.00%
|
2.48
|
| Common Stock Equity |
|
27.78
-41.09%
|
47.16
+53.35%
|
30.76
+1139.00%
|
2.48
|
| Capital Stock |
|
85.83
+9.85%
|
78.13
+65.06%
|
47.34
+112.66%
|
22.26
|
| Common Stock |
|
85.83
+9.85%
|
78.13
+65.06%
|
47.34
+112.66%
|
22.26
|
| Share Issued |
|
15.46
+11.87%
|
13.82
+47.01%
|
9.40
+169.85%
|
3.48
|
| Ordinary Shares Number |
|
15.46
+11.87%
|
13.82
+47.01%
|
9.40
+169.85%
|
3.48
|
| Additional Paid In Capital |
|
10.17
+28.68%
|
7.90
+22.06%
|
6.47
+138.17%
|
2.72
|
| Retained Earnings |
|
-81.97
-43.56%
|
-57.10
-56.59%
|
-36.46
-56.54%
|
-23.29
|
| Gains Losses Not Affecting Retained Earnings |
|
-1.72
+0.98%
|
-1.74
-579.83%
|
0.36
+7118.66%
|
-0.01
|
| Other Equity Adjustments |
|
-1.72
+0.98%
|
-1.74
-579.83%
|
0.36
+7118.66%
|
-0.01
|
| Total Equity Gross Minority Interest |
|
27.78
-41.09%
|
47.16
+53.35%
|
30.76
+1139.00%
|
2.48
|
| Total Capitalization |
|
27.78
-41.09%
|
47.16
+53.35%
|
30.76
+1139.00%
|
2.48
|
| Working Capital |
|
27.78
-41.10%
|
47.16
+69.95%
|
27.75
+6408.37%
|
-0.44
|
| Invested Capital |
|
27.78
-41.09%
|
47.16
+53.35%
|
30.76
+1139.00%
|
2.48
|
| Net Tangible Assets |
|
27.78
-41.09%
|
47.16
+53.35%
|
30.76
+7731.09%
|
-0.40
|
| Tangible Book Value |
|
27.78
-41.09%
|
47.16
+53.35%
|
30.76
+7731.09%
|
-0.40
|
| Other Equity Interest |
|
15.48
-22.47%
|
19.97
+53.00%
|
13.05
+1521.93%
|
0.80
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-23.60
-29.28%
|
-18.25
-109.00%
|
-8.73
-104.95%
|
-4.26
|
| Cash Flow From Continuing Operating Activities |
|
-23.60
-29.28%
|
-18.25
-109.00%
|
-8.73
-110.03%
|
-4.16
|
| Net Income From Continuing Operations |
|
-24.87
-20.54%
|
-20.63
-72.28%
|
-11.98
-43.57%
|
-8.34
|
| Depreciation Amortization Depletion |
|
0.00
-73.33%
|
0.01
+184.27%
|
0.01
-97.87%
|
0.25
|
| Depreciation |
|
0.00
-73.33%
|
0.01
+184.27%
|
0.01
+79.04%
|
0.00
|
| Amortization Cash Flow |
|
—
|
—
|
0.00
-100.00%
|
0.25
|
| Depreciation And Amortization |
|
0.00
-73.33%
|
0.01
+184.27%
|
0.01
-97.87%
|
0.25
|
| Amortization Of Intangibles |
|
—
|
—
|
0.00
-100.00%
|
0.25
|
| Other Non Cash Items |
|
—
|
-0.36
-368.32%
|
0.13
+229.34%
|
-0.10
|
| Stock Based Compensation |
|
3.23
+97.14%
|
1.64
+0.37%
|
1.64
+54.10%
|
1.06
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
2.90
|
0.00
-100.00%
|
2.13
|
| Operating Gains Losses |
|
-0.48
+54.68%
|
-1.07
-189.56%
|
1.19
+6373.96%
|
0.02
|
| Gain Loss On Investment Securities |
|
—
|
0.00
+497.98%
|
-0.00
+97.73%
|
-0.03
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.48
+54.81%
|
-1.07
-222.80%
|
0.87
+1590.98%
|
0.05
|
| Change In Working Capital |
|
-1.48
-96.28%
|
-0.75
-370.71%
|
0.28
-61.91%
|
0.73
|
| Change In Receivables |
|
0.07
+303.13%
|
-0.03
+86.86%
|
-0.24
-223.76%
|
0.20
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
-2.04
-17.95%
|
-1.73
-2153.92%
|
-0.08
-5117.64%
|
-0.00
|
| Change In Payables And Accrued Expense |
|
0.50
-50.49%
|
1.01
+69.08%
|
0.60
+11.89%
|
0.53
|
| Investing Cash Flow |
|
-9.42
-302.26%
|
4.66
+135.22%
|
-13.22
-597984.67%
|
-0.00
|
| Cash Flow From Continuing Investing Activities |
|
-9.42
-302.26%
|
4.66
+135.22%
|
-13.22
-597984.67%
|
-0.00
|
| Net PPE Purchase And Sale |
|
-0.01
-50.00%
|
-0.00
+70.52%
|
-0.01
-513.84%
|
-0.00
|
| Purchase Of PPE |
|
-0.01
-50.00%
|
-0.00
+70.52%
|
-0.01
-513.84%
|
-0.00
|
| Capital Expenditure |
|
-0.01
-50.00%
|
-0.00
+70.52%
|
-0.01
-513.84%
|
-0.00
|
| Net Investment Purchase And Sale |
|
-9.41
-301.95%
|
4.66
+135.29%
|
-13.21
|
0.00
|
| Purchase Of Investment |
|
-23.37
+14.76%
|
-27.42
-107.59%
|
-13.21
|
0.00
|
| Sale Of Investment |
|
13.96
-56.48%
|
32.08
|
0.00
|
—
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
2.24
-94.04%
|
37.57
-1.16%
|
38.01
+1759.18%
|
2.04
|
| Cash Flow From Continuing Financing Activities |
|
2.24
-94.04%
|
37.57
-1.50%
|
38.15
+1765.70%
|
2.04
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
+100.00%
|
-0.28
|
0.00
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
1.69
|
0.00
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-1.98
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
1.69
|
0.00
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-1.98
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-0.28
|
0.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
30.06
+22.83%
|
24.47
+1096.82%
|
2.04
|
| Cash Dividends Paid |
|
—
|
—
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
2.24
-70.19%
|
7.52
-45.64%
|
13.83
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
0.45
|
—
|
| Changes In Cash |
|
-30.77
-228.33%
|
23.98
+49.30%
|
16.06
+859.23%
|
-2.12
|
| Effect Of Exchange Rate Changes |
|
0.50
+185.84%
|
-0.59
+33.16%
|
-0.88
-1465.56%
|
-0.06
|
| Beginning Cash Position |
|
40.07
+140.23%
|
16.68
+1050.16%
|
1.45
-59.59%
|
3.59
|
| End Cash Position |
|
9.80
-75.53%
|
40.07
+140.91%
|
16.63
+1073.39%
|
1.42
|
| Free Cash Flow |
|
-23.60
-29.28%
|
-18.26
-108.73%
|
-8.75
-105.16%
|
-4.26
|
| Common Stock Issuance |
|
0.00
-100.00%
|
30.06
+22.83%
|
24.47
+1096.82%
|
2.04
|
| Interest Paid CFF |
|
—
|
—
|
-0.07
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
30.06
+22.83%
|
24.47
+1096.82%
|
2.04
|
| Sale Of Business |
|
—
|
—
|
—
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|